Erinn Bruno Rankin

Erinn Bruno Rankin is a notable inventor based in Waltham, MA, who has made significant contributions to the field of biotechnology. With a total of six patents to his name, Rankin's work primarily focuses on therapeutic applications aimed at combating various diseases, including cancer and liver fibrosis.

Latest Patents

Among his latest patents, Rankin has developed modified AXL peptides that inhibit AXL signaling in anti-metastatic therapy. This innovative approach provides compositions and methods for alleviating cancer in mammals by administering a pharmaceutical composition that inhibits the activity of AXL, MER, or Tyro3 protein activity. This is achieved through competitive or non-competitive inhibition of the binding interaction between these proteins and their ligand, GAS6. Another significant patent addresses the inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis. This patent outlines methods for alleviating endometriosis, kidney disease, inflammatory disease, and transplant rejection by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER, or Tyro3 protein activity.

Career Highlights

Throughout his career, Rankin has worked with prestigious institutions, including Leland Stanford Junior University and Aravive Biologics, Inc. His experience in these organizations has allowed him to collaborate with leading experts in the field, further enhancing his innovative contributions.

Collaborations

Rankin has collaborated with notable professionals such as Amato J Giaccia and Jennifer R Cochran, which has enriched his research and development efforts.

Conclusion

Erinn Bruno Rankin's innovative work in biotechnology, particularly in the development of therapeutic applications for cancer and liver fibrosis, showcases his significant contributions to the field. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.